{
    "id": "5c010e09133db5eb78000024",
    "question": "Can simvastatin alleviate depressive symptoms?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "A",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to analyze the provided documents and look for information related to the use of simvastatin and its effects on depressive symptoms. From Document [1], we know that statins, including simvastatin, inhibit HMG-CoA reductase, the enzyme that catalyzes the rate-limiting step in cholesterol synthesis. Additionally, from Document [12], we see that St. John's Wort can increase the metabolism of atorvastatin, lovastatin, and simvastatin, which could potentially lead to decreased levels of these medications and reduced efficacy. However, there is no direct information in the provided documents about the effect of simvastatin on depressive symptoms. From Document [14], we know that statins are effective in reducing LDL cholesterol, but we do not have information about their effects on depressive symptoms. From Document [16], we see that St. John's Wort may alleviate symptoms of mild to moderate major depression, but this is not related to simvastatin. From Document [23], we learn that antidepressants, including selective serotonin reuptake inhibitors, can reduce glutamatergic transmission, but we do not have information about simvastatin's effect on glutamate release. From Document [24], we know that simvastatin is used to treat high cholesterol, but we do not have information about its effect on depressive symptoms. From Document [25], we see that some antidepressants, including selective serotonin reuptake inhibitors, may be associated with an increased risk of major depression, but this is not related to simvastatin. From Document [26], we learn that antidepressants, including SSRIs, can be effective in treating depression in the elderly, but we do not have information about simvastatin's effect on depressive symptoms in this population. From Document [27], we see that antidepressants can reduce glutamatergic transmission, but this is not related to simvastatin. From Document [28], we know that simvastatin is used to treat high cholesterol, but we do not have information about its effect on depressive symptoms. Based on the provided information, there is no clear evidence that simvastatin alleviates depressive symptoms. However, it is worth noting that Document [4] mentions that statins are better tolerated than other lipid-lowering drugs, but also lists side effects such as muscle weakness and myalgias, which could be related to simvastatin. Despite this, the documents do not provide a clear indication that simvastatin has a direct effect on depressive symptoms. Therefore, the most appropriate answer would be B. no, but it is also worth noting that the evidence is not strong, and further research may be needed to fully understand the relationship between simvastatin and depressive symptoms.\", \"answer_choice\": \"B\"}",
    "snippets": [
        {
            "id": "Pharmacology_Katzung_7178",
            "title": "Pharmacology_Katzung",
            "content": "Garlic has shown significant benefits in lowering total choles-terol, LDL, and systolic and diastolic blood pressure, but the effects are moderate and unlikely to be large enough to lower this patient\u2019s values into the normal range. While this patient\u2019s diabetes is under control, her hypertension places her at risk for microvascular complications of diabetes, thus making it necessary to reevaluate her current medication adherence, doses of benazepril for hypertension and simvastatin for hyper-lipidemia, and duration of therapy. She would benefit from meeting with a nutritionist because packaged frozen dinners can be high in sodium, and this may be elevating her blood pressure. Adding exercise to her weekly routine could also help with weight control and overall cardiovascular health. The data supporting benefits of St. John\u2019s wort in patients with hot flashes are preliminary but show promise. Good data support use of the herb to alleviate symptoms of mild to moderate depression when"
        },
        {
            "id": "Gynecology_Novak_891",
            "title": "Gynecology_Novak",
            "content": "A) reductase inhibitors (statins) include atorvastatin, \ufb02uvastatin, lovastatin, pravastatin, and simvastatin. These medicines inhibit HMG-CoA reductase, the enzyme that catalyzes the rate-limiting step in cholesterol synthesis. Several clinical trials showed that pravastatin, simvastatin, and lovastatin have a beneficial effect in cardiovascular disease. Statins are better tolerated than other lipid-lowering drugs, but reported side effects include severe myalgias, muscle weakness with increases in creatine phosphokinase, and, rarely, rhabdomyolysis, leading to renal failure."
        },
        {
            "id": "Pharmacology_Katzung_7289",
            "title": "Pharmacology_Katzung",
            "content": "Macrolide antibiotics: [P] Clarithromycin and erythromycin inhibit the elimination of statins. Nefazodone: [NP] Decreased atorvastatin, lovastatin, and simvastatin metabolism. Phenytoin: [P] Increased atorvastatin, lovastatin, and simvastatin metabolism. Rifampin: [P] Increased atorvastatin, lovastatin, and simvastatin metabolism. St. John\u2019s wort: [NP] Increased atorvastatin, lovastatin, and simvastatin metabolism. See also Azole antifungals; Calcium channel blockers; Cyclosporine. Methyldopa: [NE] Decreased methyldopa absorption. Mycophenolate: [P] Decreased mycophenolate absorption. Quinolones: [P] Decreased absorption of ciprofloxacin and other quinolones. Tetracyclines: [P] Decreased absorption of tetracyclines; decreased efficacy of iron. Thyroid hormones: [P] Decreased thyroxine absorption. See also Antacids. Clonidine: [NE] Inhibited antiparkinsonism effect. Haloperidol: [NP] Inhibited antiparkinsonism effect."
        },
        {
            "id": "Pharmacology_Katzung_3236",
            "title": "Pharmacology_Katzung",
            "content": "The diagnosis of depression still rests primarily on the clinical interview. Major depressive disorder (MDD) is characterized by depressed mood most of the time for at least 2 weeks or loss of interest or pleasure in most activities, or both. In addition, depression is characterized by disturbances in sleep and appetite as well as deficits in cognition and energy. Thoughts of guilt, worthlessness, and suicide are common. Coronary artery disease, diabetes, and stroke appear to be more common in depressed patients, and depression may considerably worsen the prognosis for patients with a variety of comorbid medical conditions."
        },
        {
            "id": "Neurology_Adams_12195",
            "title": "Neurology_Adams",
            "content": "Because many depressed patients are responsive to one of the tricyclic drugs, MAO inhibitors, or serotonin agonists but not to all of them, the clinician is greatly aided by information regarding which of these drugs has been helpful in past episodes. As mentioned, response to antidepressant drugs is not expected for several weeks. Treatment, if successful, should be continued for 6 to 9 months and generally combined with some type of psychotherapy. The premature discontinuation of medications is a major source of relapse. The dosage of medication may then be reduced slowly over a period of weeks. Rapid reduction may result in withdrawal symptoms (nausea, vomiting, malaise, and muscular pains). If depressive symptoms recur upon withdrawal, the effective dose should be gradually reinstituted. Mann (2005) provides a thorough review of the medical treatment of depression; the side effects of each are given in tabular form and adapted for Table 48-3."
        },
        {
            "id": "Pharmacology_Katzung_7288",
            "title": "Pharmacology_Katzung",
            "content": "Lithium Renal lithium excretion sensitive to changes in sodium balance. (Sodium depletion tends to cause lithium retention.) Susceptible to drugs enhancing central nervous system lithium toxicity. Gemfibrozil: [NP] Increased plasma lovastatin and simvastatin and increased risk of myopathy. Kinase inhibitors: [P] Decreased metabolism of atorvastatin, lovastatin, and simvastatin by ceritinib, dasatinib, imatinib, idelalisib, and lapatinib."
        },
        {
            "id": "InternalMed_Harrison_31682",
            "title": "InternalMed_Harrison",
            "content": "The reported prevalence of depression in patients with diabetes mellitus varies from 8 to 27%, with the severity of the mood state correlating with the level of hyperglycemia and the presence of diabetic complications. Treatment of depression may be complicated by effects of antidepressive agents on glycemic control. MAOIs can induce hypoglycemia and weight gain, whereas TCAs can produce hyperglycemia and carbohydrate craving. SSRIs and SNRIs, like MAOIs, may reduce fasting plasma glucose, but they are easier to use and may also improve dietary and medication compliance."
        },
        {
            "id": "Pharmacology_Katzung_3849",
            "title": "Pharmacology_Katzung",
            "content": "A 42-year-old woman has heterozygous familial hyper-cholesterolemia (HeFH) but is otherwise well and has no symptoms of coronary or peripheral vascular disease. A carotid ultrasound was normal. Her mother had a myo-cardial infarction at age 51 and had no known risk factors other than her presumed HeFH. The patient also has ele-vated lipoprotein (a) at 2.5 times normal and low HDL-C (43 mg/dL). She developed muscle symptoms with each of 3 statins (atorvastatin, rosuvastatin, and simvastatin) so they were discontinued although she did not develop elevated levels of creatine kinase. Her untreated LDL-C is 235 mg/dL and triglycerides 125 mg/dL. Her LDL-C goal for primary prevention of arteriosclerotic vascular disease is in the 70-mg/dL range because of her multiple lipopro-tein risk factors and her mother\u2019s history of premature coronary artery disease. She has no other risk factors and her diet and exercise habits are excellent. How would you manage this patient?"
        },
        {
            "id": "Neurology_Adams_11530",
            "title": "Neurology_Adams",
            "content": "With the widespread use of these lipid-lowering medications, myotoxicity has become a well-described but possibly overrated problem. Symptoms range in severity from mild muscular aches with slightly elevated CK concentrations in the serum to a rare but potentially fatal rhabdomyolytic syndrome. (Myalgias alone are as common in patients taking placebo as in those taking stains). The incidence of true myopathy with statins has been estimated to be approximately 1 in 10,000 people treated per year. There appear to be two types of mypathy\u2014one idiosyncratic and associated with direct toxicity and another, now thought to be more common, due to an antibody reaction. The first generation of these drugs were fungal metabolites (lovastatin, pravastatin, simvastatin) and were infrequently implicated in muscle damage, but the newer synthetic ones (atorvastatin, fluvastatin, cerivastatin) are more frequently toxic, especially when given with gemfibrozil (which has reportedly led to a small number"
        },
        {
            "id": "InternalMed_Harrison_31616",
            "title": "InternalMed_Harrison",
            "content": "There is increasing evidence for the involvement of inflammatory mechanisms in a subset of depressed patients. These individuals display elevated blood levels of interleukin 6 (IL-6), tumor necrosis factor \u03b1 (TNF-\u03b1), and other cytokines. Moreover, rodents exposed to chronic stress exhibit similar increases in peripheral cytokines, and peripheral or central delivery of those cytokines to normal rodents increases their susceptibility to chronic stress. These findings have led to the novel idea of using peripheral cytokines as biomarkers of a subtype of depression and the potential utility of developing new antidepressants that oppose cytokine action."
        },
        {
            "id": "Pharmacology_Katzung_7179",
            "title": "Pharmacology_Katzung",
            "content": "data supporting benefits of St. John\u2019s wort in patients with hot flashes are preliminary but show promise. Good data support use of the herb to alleviate symptoms of mild to moderate depression when used for up to 1 year. However, this patient is not a good candidate for St. John\u2019s wort (a cytochrome P450 1A2, 2C9, 3A4 inducer) because of her prescription drug use and the potential for herb-drug interactions. Several dietary supplements reviewed in this chapter (garlic, ginkgo, and gin-seng) may have antiplatelet effects that could be additive with ibuprofen. If this patient were also taking warfarin, additional interactions could occur with coenzyme Q10 (vitamin K-like structure), St. John\u2019s wort, and melatonin (in vitro decreased prothrombin time), leading to a decreased warfarin effect, or with glucosamine (increased international normalized ratio), leading to an increased warfarin effect."
        },
        {
            "id": "Pharmacology_Katzung_3259",
            "title": "Pharmacology_Katzung",
            "content": "Finally, sex steroids are also implicated in the pathophysiology of depression. Estrogen deficiency states, which occur in the postpartum and postmenopausal periods, are thought to play a role in the etiology of depression in some women. Likewise, severe testosterone deficiency in men is sometimes associated with depressive symptoms. Hormone replacement therapy in hypogonadal men and women may be associated with an improvement in mood and depressive symptoms. Integration of Hypotheses Regarding the Pathophysiology of Depression"
        },
        {
            "id": "Pharmacology_Katzung_7286",
            "title": "Pharmacology_Katzung",
            "content": "Amiodarone: [NP] Decreased atorvastatin, lovastatin, and simvastatin metabolism. Expect similar interactions with dronedarone. Antivirals: [P] Amprenavir, atazanavir, boceprevir, darunavir, delavirdine, fosamprenavir, indinavir, nelfinavir, ritonavir, saquinavir, simeprevir, and telaprevir inhibit the metabolism of atorvastatin, lovastatin, and simvastatin. Bosentan: [P] Increased atorvastatin, lovastatin, and simvastatin metabolism. Carbamazepine: [P] Increased atorvastatin, lovastatin, and simvastatin metabolism. Clofibrate: [NP] Increased risk of myopathy. Cobicistat: [P] Decreased metabolism of atorvastatin, lovastatin, and simvastatin. Conivaptan: [P] Decreased metabolism of atorvastatin, lovastatin, and simvastatin. Cyclosporine: [P] Decreased atorvastatin, lovastatin, rosuvastatin, pitavastatin, and simvastatin elimination."
        },
        {
            "id": "Pharmacology_Katzung_3238",
            "title": "Pharmacology_Katzung",
            "content": "The primary indication for antidepressant agents is the treatment of MDD. Major depression, with a lifetime prevalence of around 17% in the USA and a point prevalence of 5%, is associated with substantial morbidity and mortality. MDD represents one of the most common causes of disability in the developed world. In addition, major depression is commonly associated with a variety of medical conditions\u2014from chronic pain to coronary artery disease. When depression coexists with other medical conditions, the patient\u2019s disease burden increases, and the quality of life\u2014and often the prognosis for effective treatment\u2014decreases significantly."
        },
        {
            "id": "Pharmacology_Katzung_509",
            "title": "Pharmacology_Katzung",
            "content": "Example: HMG-coenzyme A (CoA) reductase inhibitors (statins) are highly effective medications that are widely prescribed to reduce serum lipids for the prevention of cardiovascular events (Chapter 35). Seven statins in use currently are generally safe and well-tolerated, but skeletal muscle toxicity can limit their use. Known risk factors include high statin dose, interacting medications, advanced age, and metabolic comorbidities. Furthermore, the common variant, rs4149056 in SLCO1B1, increases systemic exposure of simvastatin (221% increase in plasma area under the curve for patients homozygous for the rs4149056 variant, eg, SLCO1B1*5/*5; *5/[*15 or *17]; or [*15 or *17]/[*15 or *17]) and was identified to have the single strongest association with simvastatin-induced myopathy in a GWA analysis. For individuals receiving simvastatin with reduced OATP1B1 function (at least one nonfunctional allele), CPIC recommends a lower simvastatin dose or an alternative statin (Table 5\u20132)."
        },
        {
            "id": "InternalMed_Harrison_727",
            "title": "InternalMed_Harrison",
            "content": "etIology Previous history of depression, family history of depression or bipolar disorder, and prior suicide attempts are associated with increased risk for depression among terminally ill patients. Other symptoms, such as pain and fatigue, are associated with higher rates of depression; uncontrolled pain can exacerbate depression, and depression can cause patients to be more distressed by pain. Many medications used in the terminal stages, including glucocorticoids, and some anticancer agents, such as tamoxifen, interleukin 2, interferon \u03b1, and vincristine, also are associated with depression. Some terminal conditions, such as pancreatic cancer, certain strokes, and heart failure, have been reported to be associated with higher rates of depression, although this is controversial. Finally, depression may be attributable to grief over the loss of a role or function, social isolation, or loneliness."
        },
        {
            "id": "InternalMed_Harrison_31635",
            "title": "InternalMed_Harrison",
            "content": "are also effective and may specifically benefit patients who have comorbid features of atypical depression (i.e., hypersomnia and weight gain). Insomnia, orthostatic hypotension, and the need to maintain a low-tyramine diet (avoidance of cheese and wine) have limited their use, however. Antidepressants typically take 2\u20136 weeks to become effective, and doses may need to be adjusted based on the clinical response."
        },
        {
            "id": "Gynecology_Novak_890",
            "title": "Gynecology_Novak",
            "content": "The bile acid-binding resins cholestyramine and colestipol were the mainstay of therapy. Their usefulness is limited by side effects such as constipation, bloating, nausea, and heartburn, and by their tendency to interfere with the absorption of other drugs. Nicotinic acid (500 mg three times daily) decreases triglycerides, LDL, and lipoprotein (a ) and increases HDL more than any other drug. Flushing, pruritus, gastrointestinal distress, and, rarely, hepatotoxicity are a few of the adverse effects of nicotinic acid. Starting at a low dose and pretreating with aspirin 325 mg or ibuprofen 200 mg can minimize the facial \ufb02ushing. Fibric acid derivatives like clofibrate and gemfibrozil are used to lower triglycerides and increase HDL but may increase LDL in some patients. The HMG-CoA (3-hydroxy-3methyl-glutaryl-coenzyme A) reductase inhibitors (statins) include atorvastatin, \ufb02uvastatin, lovastatin, pravastatin, and simvastatin. These medicines inhibit HMG-CoA reductase, the enzyme that"
        },
        {
            "id": "Pharmacology_Katzung_3893",
            "title": "Pharmacology_Katzung",
            "content": "Because cholesterol synthesis occurs predominantly at night, reductase inhibitors\u2014except atorvastatin, rosuvastatin, and pitavastatin\u2014should be given in the evening. Absorption generally (with the exception of pravastatin and pitavastatin) is enhanced by food. Daily doses of lovastatin vary from 10 to 80 mg. Pravastatin is nearly as potent on a mass basis as lovastatin with a maximum recommended daily dose of 80 mg. Simvastatin is twice as potent and is given in doses of 5\u201380 mg daily. Because of increased risk of myopathy with the 80-mg/d dose, the U.S. Food and Drug Administration (FDA) issued labeling for scaled dosing of simvastatin and combined ezetimibe/simvastatin in 2011. Pitavastatin is given in doses of 1\u20134 mg daily. Fluvastatin appears to be about half as potent as lovastatin on a mass basis and is given in doses of 10\u201380 mg daily. Atorvastatin is given in doses of 10\u201380 mg/d, and rosuvastatin at 5\u201340 mg/d. The dose-response curves of pravastatin and especially of"
        },
        {
            "id": "InternalMed_Harrison_18296",
            "title": "InternalMed_Harrison",
            "content": "Depression is common in HFrEF, with a reported prevalence of one in five patients, and is associated with a poor quality of life, limited functional status, and increased risk of morbidity and mortality in this population. Antidepressants may improve depression, promote vascular health, and decrease systemic inflammation in HFrEF. However, the largest randomized study of depression in HFrEF, the Sertraline Against Depression and Heart Disease in Chronic Heart Failure (SADHART-CHF) trial, showed that sertraline was safe, but did not provide greater reduction in depression or improve cardiovascular status among patients with heart failure and depression compared with nurse-driven multidisciplinary management."
        },
        {
            "id": "Pharmacology_Katzung_3336",
            "title": "Pharmacology_Katzung",
            "content": "vincristine/ vinblastine, tamoxifen, zolpidem by concurrent administration of nefazodone such that a reduction in triazolam dosage by 75% is recommended. Likewise, administration of nefazodone with simvastatin has been associated with 20-fold increase in plasma levels of simvastatin."
        },
        {
            "id": "Neurology_Adams_12184",
            "title": "Neurology_Adams",
            "content": "The use of medications for depression is now so widespread that all physicians should be familiar with them. It must be acknowledged, however, that the magnitude of the effect on depression of these medications has been dominated by a few clinical trials. Meta-analyses of several large studies on the therapeutic effects of antidepressants suggest that clinical improvement attributable to the drugs themselves occurs in approximately 50 percent of patients; remarkably, an additional improvement in up to 25 percent is attributable to a placebo effect or, more likely, to the natural course of the disease. The remainder fails to improve in a timely manner or relapse while on medication. The incremental value of certain forms of psychotherapies is discussed further on."
        },
        {
            "id": "Pharmacology_Katzung_7132",
            "title": "Pharmacology_Katzung",
            "content": "use of the herb for up to 52 weeks was reported to reduce depression scores in patients with mild to moderate major depression. These data and the mechanism of action data reported above suggest a potential role for St. John\u2019s wort in relieving symptoms of mild to moderate major depression. Due to the short study duration of these clinical trials, efficacy beyond 12 weeks still requires further study."
        },
        {
            "id": "InternalMed_Harrison_31678",
            "title": "InternalMed_Harrison",
            "content": "Between 20 and 30% of cardiac patients manifest a depressive disorder; an even higher percentage experience depressive symptomatology when self-reporting scales are used. Depressive symptoms following unstable angina, myocardial infarction, cardiac bypass surgery, or heart transplant impair rehabilitation and are associated with higher rates of mortality and medical morbidity. Depressed patients often show decreased variability in heart rate (an index of reduced parasympathetic nervous system activity), which may predispose individuals to ventricular arrhythmia and increased morbidity. Depression also appears to increase the risk of developing coronary heart disease, possibly through increased platelet aggregation. TCAs are contraindicated in patients with bundle branch block, and TCA-induced tachycardia is an additional concern in patients with congestive heart failure. SSRIs appear not to induce ECG changes or adverse cardiac events and thus are reasonable first-line drugs for"
        },
        {
            "id": "Neurology_Adams_7287",
            "title": "Neurology_Adams",
            "content": "Unusually severe fatigue is another peculiar symptom of MS; it is often transient and more likely to occur when there is fever or other evidence of disease activity but it can be a persistent complaint and a source of considerable distress. Depression may play a role in these recalcitrant cases, although the response to pharmacologic agents suggests that these 2 aspects of the disease are dissociable. Thus, antidepressants often do not improve fatigue, whereas drugs that alleviate fatigue, such as modafinil and amantadine, do not function as antidepressants."
        },
        {
            "id": "Neurology_Adams_12169",
            "title": "Neurology_Adams",
            "content": "serotonin antidepressants) that were associated with a sevenfold increased risk of major depression. Not all studies agree on these points. This result has been reinforced by Caspi and colleagues who reported that a variant in the serotonin transporter correlates with an increase in depression in response to stress. Other hypotheses have postulated various susceptibility loci but again, a single gene locus seems unlikely (see Sanders et al)."
        },
        {
            "id": "Pharmacology_Katzung_3298",
            "title": "Pharmacology_Katzung",
            "content": "It is not clear whether antidepressants are useful for all subtypes of depression. For example, patients with bipolar depression may not benefit much from antidepressants even when added to mood stabilizers. In fact, the antidepressants are sometimes associated with switches into mania or more rapid cycling. There has also been some debate about the overall efficacy of antidepressants in unipolar depression, with some meta-analyses showing large effects and others showing more modest effects. Although this debate is not likely to be settled immediately, there is little debate that antidepressants have important benefits for most patients."
        },
        {
            "id": "Pharmacology_Katzung_3254",
            "title": "Pharmacology_Katzung",
            "content": "G: Major depressive disorder. N Engl J Med 2008;358:59.) use is associated with reducing glutamatergic transmission, including the presynaptic release of glutamate in the hippocampus and cortical areas. Similarly, the chronic administration of antidepressants significantly reduces depolarization-evoked release of glutamate in animal models. Stress is known to enhance the release of glutamate in rodents, and antidepressants inhibit stress-induced presynaptic release of glutamate in these models."
        },
        {
            "id": "Pharmacology_Katzung_6641",
            "title": "Pharmacology_Katzung",
            "content": "Major changes in the conditions of daily life accompany the aging process and have an impact on health. Some of these (eg, forgetting to take one\u2019s pills) are the result of cognitive changes associated with vascular or other pathology. One of the most important changes is the loss of a spouse. Others relate to economic stresses associated with greatly reduced income and, frequently, increased expenses due to illness."
        },
        {
            "id": "InternalMed_Harrison_18480",
            "title": "InternalMed_Harrison",
            "content": "In patients with severe AS (valve area <1 cm2), strenuous physical activity and competitive sports should be avoided, even in the asymptomatic stage. Care must be taken to avoid dehydration and hypovolemia to protect against a significant reduction in CO. Medications used for the treatment of hypertension or CAD, including beta blockers and angiotensin-converting enzyme (ACE) inhibitors, are generally safe for asymptomatic patients with preserved LV systolic function. Nitroglycerin is helpful in relieving angina pectoris in patients with CAD. Retrospective studies have shown that patients with degenerative calcific AS who receive HMG-CoA reductase inhibitors (\u201cstatins\u201d) exhibit slower progression of leaflet calcification and aortic valve area reduction than those who do not. However, randomized prospective studies with either high-dose atorvastatin or combination simvastatin/ezetimibe have failed to show a measurable effect on valve-related outcomes. The use of statin medications"
        },
        {
            "id": "Pharmacology_Katzung_6648",
            "title": "Pharmacology_Katzung",
            "content": "Psychiatric depression is thought to be underdiagnosed and undertreated in the elderly. The suicide rate in the over-65 age group (twice the national average) supports this view. Unfor tunately, the apathy, flat affect, and social withdrawal of major depression may be mistaken for senile dementia. Clinical evidence suggests that the elderly are as responsive to antidepressants (of all types) as younger patients but are more likely to experience adverse effects. This factor along with the reduced clearance of some of these drugs underlines the importance of careful dos ing and strict attention to the monitoring of toxic effects. Some to tricyclic antidepressants because the SSRIs have fewer auto nomic adverse effects. If a tricyclic is to be used, a drug with reduced antimuscarinic effects should be selected, eg, nortriptyline or desipramine (see Table 30\u20132)."
        },
        {
            "id": "Pharmacology_Katzung_3887",
            "title": "Pharmacology_Katzung",
            "content": "COMPETITIVE INHIBITORS OF HMG-COA REDUCTASE (REDUCTASE INHIBITORS: \u201cSTATINS\u201d) These compounds are structural analogs of HMG-CoA (3-hydroxy3-methylglutaryl-coenzyme A, Figure 35\u20133). Lovastatin, atorvastatin, fluvastatin, pravastatin, simvastatin, rosuvastatin, and pitavastatin belong to this class. They are most effective in reducing LDL. Other effects include decreased oxidative stress and vascular inflammation with increased stability of atherosclerotic lesions. It has become standard practice to initiate reductase inhibitor therapy immediately after acute coronary syndromes, regardless of lipid levels."
        }
    ],
    "scores": [
        0.035145044213650195,
        0.02619410073252924,
        0.024046221570066032,
        0.023321623731459795,
        0.02330849138446811,
        0.023281596452328163,
        0.021052444740575278,
        0.02092569786535304,
        0.02055302055302055,
        0.019501261764078362,
        0.019487807366595247,
        0.019270150297243518,
        0.01905453225660103,
        0.018829561527581327,
        0.01869812145041503,
        0.01868811202562401,
        0.018311036789297658,
        0.017980970811159493,
        0.01783749803551784,
        0.01761025720244072,
        0.01725925925925926,
        0.01683644595359366,
        0.01672194582642344,
        0.01630827908200171,
        0.016056478820442335,
        0.015343064015630388,
        0.015298427063132947,
        0.015262954155836974,
        0.014904862579281183,
        0.014827832390576088,
        0.014801938474504846,
        0.014647917332481091
    ]
}